Warren Weiss is Managing Partner at WestWave Capital. We had a terrific discussion on small exits as seen by a seasoned investor. Sramana Mitra: Warren is very well-known in the industry as “Bunny Weiss”. That’s his nickname. I’ve known him for a very long time. He was a General Partner at Foundation Capital for many
Ben Narasin: You build your business up to $5 million in revenue. It seems like a healthy lifestyle business to me. If you have a 40% gross margin, that means $2 million is flowing to you. If you can keep your operational expenses low, that can be a great living. Later, there are people who
Sramana Mitra: The most important thing is that big market opportunity. Hypergrowth is not a natural state of business. If every entrepreneur thinks that we have to achieve hypergrowth, that is not viable. Most businesses don’t have the characteristics of being able to meet that hypergrowth criteria. Ben Narasin: Absolutely agree. Venture wasn’t built to
Sramana Mitra: What is your investment thesis? Tell me a bit more about what you like to invest in? What problems in the world do you have your eye on? What segment do you specifically like? Is e-commerce still an interest? Ben Narasin: I make a very proactive effort to meet every VC in the
Sramana Mitra: Today, the industry is segmented in to pre-seed, seed, post-seed, pre-Series A, early Series A. Where are you positioning yourself? Ben Narasin: I’m happy with anything before the Series A. My focus has always been finding entrepreneurs that I believe are venture-scalable and helping them raise their first venture round. I got over
Ben Narasin is Founder and General Partner at Tenacity Venture Capital, a new Seed fund. Sramana Mitra: Let’s start by having you introduce yourself a little bit to our audience – both your personal background and the genesis of Tenacity.
Sramana Mitra: When it comes to some of the patient monitoring stuff, which is a very active category, all applications of information technology, especially the AI algorithm in drug discovery, how do you view the role of FDA or an equivalent regulatory body? Rajeev Singh-Morales: I’ll be very candid. I’m not an expert on FDA
Sramana Mitra: What trends do you see in your deal flow? Rajeev Singh-Morales: We are a fund that is mostly B2B. We don’t a have an industry focus. There are certain areas in pharma and biotech which are extraordinarily hot right now. We don’t invest in that. We do invest in digital health. That is